These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 10496883)

  • 1. Humoral and cellular immune responses in mice immunized with recombinant Mycobacterium bovis Bacillus Calmette-Guérin producing a pertussis toxin-tetanus toxin hybrid protein.
    Abomoelak B; Huygen K; Kremer L; Turneer M; Locht C
    Infect Immun; 1999 Oct; 67(10):5100-5. PubMed ID: 10496883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression and immunogenicity of pertussis toxin S1 subunit-tetanus toxin fragment C fusions in Salmonella typhi vaccine strain CVD 908.
    Barry EM; Gomez-Duarte O; Chatfield S; Rappuoli R; Pizza M; Losonsky G; Galen J; Levine MM
    Infect Immun; 1996 Oct; 64(10):4172-81. PubMed ID: 8926085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant Mycobacterium bovis BCG expressing pertussis toxin subunit S1 induces protection against an intracerebral challenge with live Bordetella pertussis in mice.
    Nascimento IP; Dias WO; Mazzantini RP; Miyaji EN; Gamberini M; Quintilio W; Gebara VC; Cardoso DF; Ho PL; Raw I; Winter N; Gicquel B; Rappuoli R; Leite LC
    Infect Immun; 2000 Sep; 68(9):4877-83. PubMed ID: 10948100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralizing antibodies and immunoprotection against pertussis and tetanus obtained by use of a recombinant pertussis toxin-tetanus toxin fusion protein.
    Boucher P; Sato H; Sato Y; Locht C
    Infect Immun; 1994 Feb; 62(2):449-56. PubMed ID: 7507893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant activity of Mycobacterium bovis BCG expressing CRM197 on the immune response induced by BCG expressing tetanus toxin fragment C.
    Mazzantini RP; Miyaji EN; Dias WO; Sakauchi D; Nascimento AL; Raw I; Winter N; Gicquel B; Rappuoli R; Leite LC
    Vaccine; 2004 Jan; 22(5-6):740-6. PubMed ID: 14741167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of neutralizing antibodies against diphtheria toxin by priming with recombinant Mycobacterium bovis BCG expressing CRM(197), a mutant diphtheria toxin.
    Miyaji EN; Mazzantini RP; Dias WO; Nascimento AL; Marcovistz R; Matos DS; Raw I; Winter N; Gicquel B; Rappuoli R; Leite LC
    Infect Immun; 2001 Feb; 69(2):869-74. PubMed ID: 11159980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of humoral immunity in response to immunization with recombinant Mycobacterium bovis BCG expressing the S1 subunit of Bordetella pertussis toxin.
    Medeiros MA; Armôa GR; Dellagostin OA; McIntosh D
    Can J Microbiol; 2005 Dec; 51(12):1015-20. PubMed ID: 16462859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tetanus toxin fragment C-specific priming by intranasal infection with recombinant Bordetella pertussis.
    Reveneau N; Alonso S; Jacob-Dubuisson F; Mercenier A; Locht C
    Vaccine; 2001 Dec; 20(5-6):926-33. PubMed ID: 11738759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and protective efficacy conferred by a novel recombinant Mycobacterium bovis bacillus Calmette-Guérin strain expressing interleukin-12p70 of human cytokine and Ag85A of Mycobacterium tuberculosis fusion protein.
    Deng YH; He HY; Zhang FJ
    Scand J Immunol; 2013 Dec; 78(6):497-506. PubMed ID: 24283772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucosal and systemic immune responses elicited by recombinant Lactococcus lactis expressing a fusion protein composed of pertussis toxin and filamentous hemagglutinin from Bordetella pertussis.
    Torkashvand A; Bahrami F; Adib M; Ajdary S
    Microb Pathog; 2018 Jul; 120():155-160. PubMed ID: 29738814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of 13 acellular pertussis vaccines: overview and serologic response.
    Edwards KM; Meade BD; Decker MD; Reed GF; Rennels MB; Steinhoff MC; Anderson EL; Englund JA; Pichichero ME; Deloria MA
    Pediatrics; 1995 Sep; 96(3 Pt 2):548-57. PubMed ID: 7659475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific lung mucosal and systemic immune responses after oral immunization of mice with Salmonella typhimurium aroA, Salmonella typhi Ty21a, and invasive Escherichia coli expressing recombinant pertussis toxin S1 subunit.
    Walker MJ; Rohde M; Timmis KN; Guzmán CA
    Infect Immun; 1992 Oct; 60(10):4260-8. PubMed ID: 1398937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine.
    Podda A; Bona G; Canciani G; Pistilli AM; Contu B; Furlan R; Meloni T; Stramare D; Titone L; Rappuoli R
    J Pediatr; 1995 Aug; 127(2):238-43. PubMed ID: 7636648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective immunogenicity of synthetic peptides selected from the amino acid sequence of Bordetella pertussis toxin subunit S1.
    Askelöf P; Rodmalm K; Wrangsell G; Larsson U; Svenson SB; Cowell JL; Undén A; Bartfai T
    Dev Biol Stand; 1991; 73():111-20. PubMed ID: 1778305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of safety and efficacy against Bordetella pertussis of a new tetanus-reduced dose diphtheria-acellular pertussis vaccine in a murine model.
    Kwon HJ; Han SB; Kim BR; Kang KR; Huh DH; Choi GS; Ahn DH; Kang JH
    BMC Infect Dis; 2017 Apr; 17(1):247. PubMed ID: 28376777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surface expression of a protective recombinant pertussis toxin S1 subunit fragment in Streptococcus gordonii.
    Lee SF; March RJ; Halperin SA; Faulkner G; Gao L
    Infect Immun; 1999 Mar; 67(3):1511-6. PubMed ID: 10024603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and protective efficacy of a newly developed tri-component diphtheria, tetanus, and acellular pertussis vaccine in a murine model.
    Huh DH; Han SB; Shin HJ; Ahn DH; Choi GS; Kang KR; Kim BR; Kang JH
    J Microbiol Immunol Infect; 2018 Dec; 51(6):732-739. PubMed ID: 28720318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pneumococcal Surface Protein A does not affect the immune responses to a combined diphtheria tetanus and pertussis vaccine in mice.
    Lima FA; Miyaji EN; Quintilio W; Raw I; Ho PL; Oliveira ML
    Vaccine; 2013 May; 31(20):2465-70. PubMed ID: 23541622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular pertussis vaccine containing a Bordetella pertussis strain that produces a nontoxic pertussis toxin molecule.
    Marsili I; Pizza M; Giovannoni F; Volpini G; Bartalini M; Olivieri R; Rappuoli R; Nencioni L
    Infect Immun; 1992 Mar; 60(3):1150-5. PubMed ID: 1541530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Bivalent Recombinant
    Kanno AI; Goulart C; Leite LCC; Pagliarone AC; Nascimento IP
    Biomed Res Int; 2019; 2019():9630793. PubMed ID: 30941374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.